News

EVELO BIOSCIENCES AND MAYO CLINIC COLLABORATE TO ADVANCE MONOCLONAL MICROBIALS FOR THE TREATMENT OF INFLAMMATORY AND NEUROINFLAMMATORY DISEASES
Cambridge, Mass. - November 16, 2017

EVELO BIOSCIENCES ANNOUNCES $50 MILLION SERIES B FINANCING AND EXPANSION OF BOARD AND LEADERSHIP TEAM
Cambridge, Mass. - July 11, 2017

EVELO BIOSCIENCES TO PRESENT AT BIOCENTURY NEWSMAKERS CONFERENCE
Cambridge, Mass. - September 6, 2016

EVELO BIOSCIENCES AND MAYO CLINIC ESTABLISH RESEARCH COLLABORATION FOR IMMUNO-MICROBIOME CANCER THERAPIES
Cambridge, Mass. - August 2, 2016

EVELO BIOSCIENCES AND EPIVA BIOSCIENCES MERGE TO CREATE THE LEADING IMMUNO-MICROBIOME COMPANY
Cambridge, Mass. - July 12, 2016

EVELO BIOSCIENCES PARTICIPATES IN WHITE HOUSE OFFICE OF SCIENCE AND TECHNOLOGY POLICY'S NATIONAL MICROBIOME INITIATIVE EVENT
Cambridge, Mass. - May 13, 2016

EVELO BIOSCIENCES ANNOUNCES PARTICIPATION AT GUGGENHEIM MICROBIOME DAY
Cambridge, Mass. - April 14, 2016

UCHICAGO AND EVELO BIOSCIENCES SIGN LICENSING DEAL FOR MICROBIOME-BASED CANCER IMMUNOTHERAPY
Cambridge, Mass. - April 7, 2016

EVELO BIOSCIENCES ESTABLISHES SCIENTIFIC ADVISORY BOARD
Cambridge, Mass. - March 29, 2016

EVELO THERAPEUTICS ESTABLISHES CORE EXECUTIVE TEAM
Cambridge, Mass. - January 11, 2016

EVELO THERAPEUTICS EXPANDS TO NEW HEADQUARTERS IN CAMBRIDGE
Cambridge, Mass. - December 18, 2015

UCHICAGO AND EVELO THERAPEUTICS PARTNER TO ADVANCE MICROBIOME-BASED CANCER IMMUNOTHERAPY
Cambridge, Mass. - November 9, 2015

FLAGSHIP VENTURES LAUNCHES EVELO THERAPEUTICS TO DEVELOP MICROBIOME THERAPIES FOR CANCER
Cambridge, Mass. - November 4, 2015